AMRX - Amneal Pharmaceuticals, Inc.

NYSE - NYSE Delayed Price. Currency in USD
3.4000
+0.0100 (+0.29%)
At close: 4:00PM EDT

3.4000 0.00 (0.00%)
After hours: 5:19PM EDT

Stock chart is not supported by your current browser
Previous Close3.3900
Open3.3800
Bid3.3000 x 3000
Ask3.3800 x 3100
Day's Range3.2600 - 3.4200
52 Week Range3.1800 - 24.4800
Volume1,455,772
Avg. Volume1,565,491
Market Cap1.016B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.9450
Earnings DateAug 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.59
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Amneal Pharmaceuticals, Inc. - AMRX

    Pomerantz LLP is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (AMRX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.

  • GlobeNewswire5 days ago

    ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Amneal Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. (“Amneal” or “the Company”) (NYSE: AMRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

  • Benzinga5 days ago

    Morgan Stanley Downgrades Teva, Endo On Drug Pricing And Litigation Concerns

    Pharmaceutical stocks have been under pressure for the past few trading days, but one Wall Street analyst said the worst is yet to come for a handful of specialty drugmakers. The Analyst Morgan Stanley ...

  • Business Wire7 days ago

    AMNEAL INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX

    Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Amneal Pharmaceuticals, Inc. (AMRX). For many years, the Company, (formerly Impax Laboratories Inc.), which develops, manufactures, and markets bioequivalent, generic, pharmaceutical products, has been embroiled in investigations and litigation by state and federal authorities and relating to claims that it colluded with other competitor companies in a price-fixing scheme resulting in exponential price increases of certain products.

  • Amneal (AMRX) Down on Guidance Update & Restructuring Plan
    Zacks9 days ago

    Amneal (AMRX) Down on Guidance Update & Restructuring Plan

    Amneal (AMRX) slumps on news of budget cut and reduction in annual guidance.

  • Business Wire9 days ago

    INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Amneal Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. (“Amneal” or “the Company”) (NYSE: AMRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

  • ACCESSWIRE9 days ago

    Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX)

    NEW YORK, NY / ACCESSWIRE / July 11, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amneal Pharmaceuticals, Inc. (“Amneal ” or the “Company”) (NYSE: ...

  • Business Wire9 days ago

    EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Amneal Pharmaceuticals, Inc. – AMRX

    Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Amneal Pharmaceuticals, Inc. resulting from allegations that Amneal may have issued materially misleading business information to the investing public.

  • Benzinga9 days ago

    The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 10) CONMED Corporation (NASDAQ: CNMD ) Eidos Therapeutics ...

  • Business Wire9 days ago

    INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Amneal Pharmaceuticals, Inc. and Encourages Investors With Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. (“Amneal” or “the Company”) (NYSE: AMRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

  • Why Micro Focus International, MSC Industrial Direct, and Amneal Pharmaceuticals Slumped Today
    Motley Fool10 days ago

    Why Micro Focus International, MSC Industrial Direct, and Amneal Pharmaceuticals Slumped Today

    Company-specific bad news kept these stocks out of the rally.

  • Here's Why Amneal Pharmaceuticals Fell as Much as 36.6% Today
    Motley Fool10 days ago

    Here's Why Amneal Pharmaceuticals Fell as Much as 36.6% Today

    Stubborn headwinds in the generic-drug markets are forcing the company to restructure operations.

  • Benzinga10 days ago

    Amneal Announces Restructuring Plan, Cuts Guidance

    Amneal Pharmaceuticals (NYSE: AMRX) has reduced EBITDA for 2019 to now be in the range of $425 million to $475 million. Amneal said it factored in continuing market pressure and additional competition on its key generic products, the uncertainty of supply of epinephrine auto-injector (generic Adrenaclick) from its third-party supplier during the high seasonal third quarter, as well as delays in key product approvals and launches including generic NuvaRing. “Recently we initiated an in depth, company-wide review of our organizational structures, operational budgets, current and future capital projects, and existing capability and infrastructure alignments,” said CEO Rob Stewart.

  • Reuters10 days ago

    UPDATE 1-Amneal Pharma cuts core profit forecast on allergy shot supply issues

    Amneal Pharmaceuticals Inc on Wednesday cut its 2019 core earnings forecast, citing the uncertain supply of epinephrine auto-injectors amid a global shortage of the emergency allergy shots, including Mylan NV's EpiPen. Amneal now expects full-year adjusted earnings before interest, tax, depreciation and amortization in the range $425 million to $475 million, compared with its previous forecast of $600 million to $650 million. The supply disruption has plagued Amneal for over a year, and the company saw its 2018 combined generics net revenue fall 2.6%, hurt mainly by lower sales of its epinephrine auto-injector.

  • Business Wire10 days ago

    Amneal Pharmaceuticals Announces Restructuring and Costs Savings Plan to Improve Operations and Position the Company for Future Growth

    Amneal Pharmaceuticals, Inc. (AMRX) today announced a comprehensive restructuring plan designed to reduce its cost base, further right size its organization and optimize its global manufacturing infrastructure. “Recently we initiated an in depth, company-wide review of our organizational structures, operational budgets, current and future capital projects, and existing capability and infrastructure alignments,” said Rob Stewart, President and Chief Executive Officer of Amneal. “We undertook this review in response to the continuing industry challenges impacting our business, including ongoing pressure on our base generics business from the limited number of buyers and the greater than expected effect of additional competition on our key generic products.

  • Business Wire11 days ago

    Amneal to Report Second Quarter 2019 Results on August 8, 2019

    Amneal Pharmaceuticals, Inc. will release its second quarter 2019 financial results on Thursday, August 8, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m.

  • GlobeNewswire23 days ago

    Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Rockwell Medical, Amneal Pharmaceuticals and Intuit and Encourages Investors to Contact the Firm

    Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Rockwell Medical, Inc., Amneal Pharmaceuticals, Inc., and Intuit, Inc. Additional information about each case can be found at the link provided.

  • GlobeNewswirelast month

    Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Rockwell Medical, Amneal Pharmaceuticals, Kraft Heinz, and Intuit and Encourages Investors to Contact the Firm

    NEW YORK, June 18, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Rockwell Medical, Amneal Pharmaceuticals,.

  • AMNEAL INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX
    PR Newswirelast month

    AMNEAL INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX

    NEW ORLEANS , June 14, 2019 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF ...

  • Barclays Has New Plays for Healthcare Fans
    SmarterAnalystlast month

    Barclays Has New Plays for Healthcare Fans

    Investment banker Barclays announced it has initiated coverage of 20 U.S. specialty pharmaceuticals stocks.But which 20 stocks within this sector are we talking about today? They include generic drugs companies Mylan (MYL), which Barclays rates Overweight (i.e. 'buy') and Teva Pharmaceutical Industries (TEVA), which the analyst rates Underweight (i.e. 'sell'), as well as: * Amneal Pharmaceuticals (AMRX) * Endo International (ENDP) * Reddy's Laboratories (RDY) * and Mallinckrodt plc (MNK)Each of which is rated Equal weight (i.e. 'hold').Within the animal health sector (i.e. veterinary medicine), Barclays initiates coverage with Overweight ratings on Zoetis (ZTS) and Kindred Biosciences (KIN), but gives Phibro Animal Health Corporation (PAHC) an Underweight rating.Among developmental and commercial stage companies "with unique products & segments," Barclays has two 'sells' -- Allergan (AGN) and Evolus (EOLS) -- and one hold: Ligand Pharmaceuticals (LGND). As for Barclays' 'buy' ratings, it rates the following companies Overweight ratings: * AMAG Pharmaceuticals (AMAG) * Jazz Pharmaceuticals (JAZZ) * Osmotica Pharmaceuticals (OSMT) * Coherus BioSciences (CHRS) * Pacira BioSciences (PCRX) * Revance Therapeutics (RVNC) * Bausch Health Companies (BHC) * and Foamix Pharmaceuticals (FOMX)Today, we really only have time to glance at just one of these stocks: Rehovot, Israel-based Foamix.Foamix is a late clinical-stage specialty pharmaceutical company focusing on foam-based medications for the treatment of acne and rosacea. Foamix stands out in this report primarily by virtue of the extremely high hopes Barclays'  has for it, namely, valued at just $2.53 per share today, Barclays believes that within a year, Foamix stock will be selling for $10 -- a four-bagger in just one year.Why is Barclays so optimistic? As the analyst explains, Foamix is on the cusp of becoming a "commercial stage company" -- i.e. a company with actual revenue from sales, a rarity in small drugs stocks -- thanks to its topical Minocycline product for acne and rosacea. Designated "FMX-101" for acne treatment and "FMX-103" for rosacea, both these foam-based products "combine [the] proven efficacy of minocycline with a more tolerable side effect profile" says Barclays. From $3 million in annual revenue today, the banker predicts Foamix could do as much as $272 million in annual sales by 2025E.Considering that the entire company has a market cap of barely half that number -- $138 million -- today, Foamix at least seems to have earned its place on Barclays' list.Foamix has a few upcoming catalysts that could send its shares surging higher: * There is a scheduled PDUFA for FMX-101 on October 20, 2019. This is a key event for Foamix, as FMX-101 is its lead product in acne. * Foamix anticipates filing an NDA in mid-2019 for FMX-103 in moderate-to-severe papulopustular rosacea. * FCD-105 Phase II study initiation in mid-2019: FCD-105 is another pipeline product being evaluated in patients with acne and is a foam-based combination of minocycline and adapalene."We value Foamix on a DCF basis, assuming an 11.5% discount rate and a 3% terminal growth. We include risk adjusted pipeline values for both FMX-101 (90% probability of success) and FMX-103 (70% probability of success). We also assume base uptake of FMX-101, reaching 2025 risk-adj. sales of ~$200mm. This scenario yields a value of ~$10/share and serves as the basis for our price target," Barclays noted.Read more: Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now More recent articles from Smarter Analyst: * Curaleaf Helping to Put U.S. Cannabis Sector on the Map * Netflix’s (NFLX) Original Content Strategy Is Failing; The Stock Is Overvalued * Marijuana Stock KushCo (KSHB): Potential Catalysts Vs. Risks * Evercore Continues to Hold a Bullish View on Bank of America (BAC) Stock

  • Drugmakers raised prices of over 40 prescription drugs
    Yahoo Finance Video18 days ago

    Drugmakers raised prices of over 40 prescription drugs

    Yahoo Finance’s Adam Shapiro, Sibile Marcellus, and Rick Newman join Direxion Managing Director Sylvia Jablonski to discuss.